The overall objective of this project is to gain more inside into the role of PPARγ in osteoclastogenesis, osteoclast differentiation and function.
ID
Source
Brief title
Condition
- Bone disorders (excl congenital and fractures)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Osteoclasts will be cultured under different conditions (control, with PPARγ-
agonist, with PPARγ-agonist). The overall objective of this project is to gain
more inside into the role of PPARγ in osteoclastogenesis and osteoclast
differentiation. This will be done by assessing the following:
- Osteoclast formation (by assessing the formation of tartrate-resistent acid
phosphatase positive multinucleated cells (TRACP+ MNCs))
- Osteoclast activity (by analyzing bone resorption as described previously)
- Osteoclast differentiation (will be quantified by RNA expression of PPARγ,
PGC1β, RANK, c-fms, c-fos, NFATc1, TRACP, Cathepsine K, calcitonin receptor,
DC-STAMP)
- Osteoclast function (by in vitro resorption of bone slices)
Secondary outcome
NA
Background summary
Peroxisome proliferator-activated receptor (PPAR)γ is nuclear receptor crucial
in many physiologic processes including adipogenesis, lipid metabolism and
glucose metabolism. Accumulating evidence reveals that PPARγ is also involved
in skeletal metabolism. PPARγ is a metabolic switch for stem cell fate in both
mesenchymal and hematopoeitic lineages. Although PPARγ has been shown to
inhibit osteoblast differentiation, its specific role in osteoclast function
has not been fully explored.
To gain more inside into the role of PPARγ in osteoclastogenesis and osteoclast
differentiation we are isolating peripheral blood mononuclear cells from whole
blood to form osteoclasts. These osteoclasts will be cultured under different
conditions (control, with PPARγ-agonist, with PPARγ-antagonist) to gain more
inside into the role of PPARγ in osteoclastogenesis, osteoclast differentiation
and function.
Study objective
The overall objective of this project is to gain more inside into the role of
PPARγ in osteoclastogenesis, osteoclast differentiation and function.
Study design
In vitro study with peripheral blood mononuclear cells (PBMCs) from healthy
volunteers.
Study burden and risks
Healthy participants (n=6) will visit the AMC one single time. Blood samples
will be we drawn once and the total amount of blood samples will not exceed
70ml. Participation in this study has no direct advantage for the participants.
However, the risks associated with venapunctions are negligible and little
physical or psychological discomfort associated with participation is expected.
Meibergdreef 9
Amsterdam 1105AZ
NL
Meibergdreef 9
Amsterdam 1105AZ
NL
Listed location countries
Age
Inclusion criteria
The healthy volunteer is willing and able to provide written informed consent prior to study-related procedures.
The healthy volunteer is >= 18 years of age.
Exclusion criteria
Use of anticoagulants
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL42471.018.12 |